Outsourcing-Pharma: Targeting special patient populations with the help of AI

August 2, 2018

One of the biggest challenges of clinical trials is identifying the specific patient populations. This is a factor that has become even more critical with the rise of highly targeted oncology medicines. The solution: Artificial intelligence (AI) techniques which unify structured and unstructured clinical patient data for real-time accessibility.

To meet the demand of finding patients with highly specific mutational contexts of drug sensitivity for trial participation, TD2 turned to Deep 6 AI. Using a variety of AI and natural language processing (NLP) techniques, Deep 6 AI creates “patient graphs” from structured and unstructured data from every clinical event in a patient’s life and how those events relate.

For TD2, patients can be matched against clinical trial eligibility criteria in minutes, rather than the months it currently takes.

Hear from TD2 president and CEO, Stephen Gately and Deep 6 AI cofounder and CEO, Wout Brusselaers about the partnership and what the future holds for AI in drug development in Outsourcing-Pharma.

Radiopharmaceutical Dosing Under FDA’s New Spotlight: What You Should Know

The FDA has issued a new draft guidance titled “Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development.” This ...

Read more +

Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus

In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...

Read more +

The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know

Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.